BRAF and melanoma: Reanalysis of a published dataset (GSE98314) revealed that treatment with the BRAFi Dabrafenib decreased EZH2 expression in 11 different BRAF mutated melanoma cell lines (Figure 3C) and we found a significant inverse correlation of EZH2 and miR-129 expression (r = −0.46; p = 0.029) (Figure 3D).